Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
52
MAZE Quote, Financials, Valuation and Earnings
Last price:
$17.21
Seasonality move
:
--
Day range:
$15.87 - $16.69
52-week range:
$6.71 - $17.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.38x
Volume:
122.2K
Avg. volume:
114.2K
1-year change:
--
Market cap:
$696.4M
Revenue:
$167.5M
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingMaze Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $23.00, Maze Therapeutics has an estimated upside of 41.45% from its current price of $16.26.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.00 representing 100% downside risk from its current price of $16.26.
Fair Value
-
According to the consensus of 4 analysts, Maze Therapeutics has 41.45% upside to fair value with a price target of $23.00 per share.
MAZE vs. S&P 500
-
Over the past 5 trading days, Maze Therapeutics has overperformed the S&P 500 by 7.76% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Maze Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Maze Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Maze Therapeutics reported revenues of --.
Earnings Growth
-
Maze Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Maze Therapeutics reported earnings per share of --.
Enterprise value:
402M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
8.01x
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
5.85x
Price / Operating cash flow:
9.46x
Enterprise value / EBITDA:
7.55x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | $50.2M | -$28M | -$35.4M | |
| EBITDA | -- | -- | $53.2M | -$27.1M | -$34.7M | |
| Diluted EPS | -- | -- | -$1.24 | -$0.93 | -$1.15 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | $299.7M | |
| Total Assets | -- | -- | -- | -- | $332.8M | |
| Current Liabilities | -- | -- | -- | -- | $18.6M | |
| Total Liabilities | -- | -- | -- | -- | $40.8M | |
| Total Equity | -- | -- | -- | -- | $292.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | $69.9M | -$23.4M | -$29.5M | |
| Cash From Investing | -- | -- | -$1.2M | -$279K | -$299K | |
| Cash From Financing | -- | -- | $195.6M | $24.6M | $127.4M | |
| Free Cash Flow | -- | -- | $68.7M | -$23.7M | -$29.8M | |
MAZE
Sector
Market Cap
$696.4M
--
Price % of 52-Week High
95.65%
--
Dividend Yield
0%
--
Shareholder Yield
--
--
1-Year Price Total Return
--
--
Beta (5-Year)
--
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$15.12
200-day SMA
Buy
Level
$0.00
Bollinger Bands (100)
Buy
Level
9.19 - 13.07
Chaikin Money Flow
Buy
Level
350.1K
20-day SMA
Buy
Level
$13.02
Relative Strength Index (RSI14)
Buy
Level
68.60
ADX Line
Buy
Level
34.94
Williams %R
Sell
Level
-7.5306
50-day SMA
Buy
Level
$11.94
MACD (12, 26)
Buy
Level
4.31
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
700.1K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Stock Forecast FAQ
In the current month, MAZE has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MAZE average analyst price target in the past 3 months is $23.00.
-
Where Will Maze Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Maze Therapeutics share price will rise to $23.00 per share over the next 12 months.
-
What Do Analysts Say About Maze Therapeutics?
Analysts are divided on their view about Maze Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Maze Therapeutics is a Sell and believe this share price will drop from its current level to $17.00.
-
What Is Maze Therapeutics's Price Target?
The price target for Maze Therapeutics over the next 1-year time period is forecast to be $23.00 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MAZE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Maze Therapeutics is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MAZE?
You can purchase shares of Maze Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Maze Therapeutics shares.
-
What Is The Maze Therapeutics Share Price Today?
Maze Therapeutics was last trading at $17.21 per share. This represents the most recent stock quote for Maze Therapeutics. Yesterday, Maze Therapeutics closed at $16.26 per share.
-
How To Buy Maze Therapeutics Stock Online?
In order to purchase Maze Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
